We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug Products
Books
FDAnews Books Library
Events
Form 483s Database
Subscription Newsletters
Free Newsletters
Webinar Training Pass
eCFR and Guidances
Device Products
Books
FDAnews Books Library
Events
Form 483s Database
Subscription Newsletters
Free Newsletters
Webinar Training Pass
eCFR and Guidances
Clinical Products
Advertising
White Papers
Contact Us
About Us
COVID-19
Sign In
Create Account
Sign Out
My Account
Home
» Merck Licensing HIV Experimental Drugs
Merck Licensing HIV Experimental Drugs
August 24, 2012
Merck is licensing two experimental HIV drugs from other companies and advancing one of its own into mid-stage patient testing.
Courier Post
Upcoming Events
26
Jan
Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup
27
Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
27
Jan
FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations
09
Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19
10
Feb
FDA Under the Biden Administration: What’s to Come and What It Will Mean
11
Feb
Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era
Featured Products
Biological Risk Evaluation and Management for Medical Devices
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
Featured Stories
MiRXES Earns CE Mark for COVID-19/Flu Test
Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma
Lilly’s Monoclonal Antibody Could Prevent COVID-19 in the Elderly
Fluidigm Gains CE Mark for Saliva-Based Assay for COVID-19
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
